Research guide for for athletes — mechanisms, protocols, and independent analysis from Compound Review.
Why IGF-1 LR3 Works for Athletic Performance
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analogue of IGF-1 with a modified arginine-3 substitution that reduces binding to IGF-binding proteins, extending its half-life from minutes to approximately 20–30 hours. For athletes, its primary interest is in muscle protein synthesis, satellite cell activation, and connective tissue repair — all downstream effects of GH/IGF-1 axis activation.
IGF-1 LR3 Dosage Protocol for Athletes
Athletic research protocols use 20–100 mcg subcutaneously or intramuscularly post-workout, typically in the muscle group trained. Lower doses (20–40 mcg) are used for tissue repair; higher doses (60–100 mcg) for anabolic applications. IGF-1 LR3 is typically cycled in 4-week blocks due to receptor desensitization. It is not stacked with insulin due to additive hypoglycemia risk.
IGF-1 LR3 from Purgo Labs
IGF-1 LR3 is prohibited under WADA anti-doping regulations and is not approved for human use. Evidence for athletic performance enhancement is primarily mechanistic and anecdotal — no controlled human trials exist. Hypoglycemia is the primary acute risk; long-term risks related to IGF-1 and cancer promotion are a theoretical concern that has not been quantified in research populations.